• AJAY KUMAR SHUKLA Department of Pharmacology, AIIMS Bhopal, India
  • SAURAV MISRA Department of Pharmacology, Kalpana Chawla Government Medical College, Karnal, India




Monkeypox, Orthopoxvirus genus, Tecovirimat, Newer therapeutics


The Monkeypox virus (MPXV) causative agent for Monkeypox disease resembles a smallpox-like illness and can lead to a number of serious medical issues in humans. It is an enveloped double-stranded DNA virus and belongs to the Orthopoxvirus genus. Monkeypox cases have increased after the smallpox vaccine was no longer administered. Monkeypox did not really receive widespread attention until the 2003 US outbreak. The majority of monkeypox cases connected to the 2022 outbreak are being reported in nations surrounding Europe and in the western world. The neurological, respiratory, and gastrointestinal systems are all known to be impacted. There are currently no standardised or ideal guidelines for the clinical management of patients with monkeypox (MPX), especially in low-resource settings. Patient outcomes may also be poor and their illnesses may last a long time. The range of clinical manifestations, including complications and sequelae, as well as characteristics of the illness that may be indicators of illness severity and poor outcomes, must be better understood in order to improve care. Though more research is required before they can be used in an endemic setting, new therapeutics and vaccines offer hope for the treatment and prevention of monkeypox.


Download data is not yet available.


European Centre for Disease Prevention and Control. Factsheet health prof monkeypox. Available from: https://www.ecdc.europa.eu/en/all-topics-z/monkeypox/factsheet-health-professionals#:~:text=The%20pathogen,%2Drelated%20poxviruses%20%5B2%5D. [Last accessed on 21st Sep 2022]

Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR. The changing epidemiology of human monkeypox-a potential threat? A systematic review. PLOS Negl Trop Dis. 2022 Feb 11;16(2):e0010141. doi: 10.1371/journal.pntd.0010141, PMID 35148313.

Choudhary G, Prabha PK, Gupta S, Prakash A, Medhi B. Monkeypox infection: A quick glance. Indian J Pharmacol. 2022;54(3):161-4. doi: 10.4103/ijp.ijp_400_22, PMID 35848685.

Macneil A, Reynolds MG, Braden Z, Carroll DS, Bostik V, Karem K. Transmission of atypical varicella-zoster virus infections involving palm and sole manifestations in an area with monkeypox endemicity. Clin Infect Dis. 2009;48(1):e6-8. doi: 10.1086/595552, PMID 19025497.

World Health Organization (WHO). WHO Director-General declares the ongoing monkeypox outbreak a Public Health Emergency of International Concern. Available from: https://www.who.int/europe/news/item/23-07-2022-who-director-general-declares-the-ongoing-monkeypox-outbreak-a-public-health-event-of-international-concern. [Last accessed on 21 Sep 2022]

Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB. Monkeypox virus infection in humans across 16 countries–April-June 2022. N Engl J Med. 2022;387(8):679-91. doi: 10.1056/NEJMoa2207323, PMID 35866746.

World health Organisation. Available from: https://www.who.int/news-room/fact-sheets/detail/monkeypox. [Last accessed on 21 Sep 2022]

Moore MJ, Rathish B, Zahra F. Monkeypox. StatPearls. Available from: https://www.ncbi.nlm.nih.gov/books/NBK574519.

Alakunle E, Moens U, Nchinda G, Okeke MI. Monkeypox virus in Nigeria: infection biology, epidemiology, and evolution. Viruses. 2020;12(11):1257. doi: 10.3390/v12111257, PMID 33167496.

Bookshelf Help. Bethesda: National Center for Biotechnology Information. US; 2005-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK3833. [Last accessed on 24 Dec 2022]

Velavan TP, Meyer CG. Monkeypox 2022 outbreak: an update. Trop Med Int Health. 2022;27(7):604-5. doi: 10.1111/tmi.13785, PMID 35633308.

Townsend MB, Keckler MS, Patel N, Davies DH, Felgner P, Damon IK. Humoral immunity to smallpox vaccines and monkeypox virus challenge: proteomic assessment and clinical correlations. J Virol. 2013;87(2):900-11. doi: 10.1128/JVI.02089-12, PMID 23135728.

Belongia EA, Naleway AL. Smallpox vaccine: the good, the bad, and the ugly. Clin Med Res. 2003;1(2):87-92. doi: 10.3121/cmr.1.2.87, PMID 15931293.

Center for Disease Control and Prevention. Monkey Pox Vaccin Guid. Available from: https://www.cdc.gov/poxvirus/monkeypox/clinicians/smallpox-vaccine.html. [Last accessed on 21 Sep 2022]

Rizk JG, Lippi G, Henry BM, Forthal DN, Rizk Y. Prevention and treatment of monkeypox. Drugs. 2022;82(9):957-63. doi: 10.1007/s40265-022-01742-y, PMID 35763248.

Reynolds MG, McCollum AM, Nguete B, Shongo Lushima RS, Petersen BW. Improving the care and treatment of monkeypox patients in low-resource settings: applying evidence from contemporary biomedical and smallpox biodefense research. Viruses. 2017;9(12):380. doi: 10.3390/v9120380, PMID 29231870.

Ceners for Disease Control and Prevention. Interim clinical guidance for the treatment of Monkeypox. Available from: https://www.cdc.gov/poxvirus/monkeypox/clinicians/treatment.html. [Last accessed on 21 Sep 2022]

Harris E. Global monkeypox outbreaks spur drug research for the neglected disease. JAMA. 2022;328(3):231-3. doi: 10.1001/jama.2022.11224, PMID 35767293.

Sherwat A, Brooks JT, Birnkrant D, Kim P. Tecovirimat and the treatment of monkeypox–past, present, and future considerations. N Engl J Med. 2022;387(7):579-81. doi: 10.1056/NEJMp2210125, PMID 35921403.

National Institute of Health (NIH). Natl Inst Allergy Infect Dis Monkey Pox. Available athttps://www.niaid.nih.gov/diseases-conditions/monkeypox. [Last accessed on 21 Sep 2022]

Monkey pox treatment. National Institute of Health (National Institutes of Health) National Institute of Allergy and Infectious Diseases. Available from: https://www.niaid.nih.gov/diseases-conditions/monkeypox-treatment. [Last accessed on 21 Sep 2022]

Prichard MN, Kern ER. Antiviral activity of 4′-thioIDU and thymidine analogs against orthopoxviruses. Viruses. 2010;2(9):1968-83. doi: 10.3390/v2091968, PMID 21994716.

BMJ Best practices. Monkey pox emerging treatment. Available from: https://bestpractice1611/emergingtxs.bmj.com/topics/en-us. [Last accessed on 24 Dec 2022]

Parker S, Handley L, Buller RM. Therapeutic and prophylactic drugs to treat orthopoxvirus infections. Future Virol. 2008;3(6):595-612. doi: 10.2217/17460794.3.6.595, PMID 19727418.

Baker RO, Bray M, Huggins JW. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 2003;57(1-2):13-23. doi: 10.1016/s0166-3542(02)00196-1, PMID 12615299.

Lam HYI, Guan JS, Mu Y. In silico repurposed drugs against monkeypox virus. Molecules. 2022;27(16):5277. doi: 10.3390/molecules27165277, PMID 36014515.



How to Cite

SHUKLA, A. K., and S. MISRA. “A REVIEW OF MONKEYPOX DISEASE AND FUTURE TREATMENT OPTIONS”. International Journal of Current Pharmaceutical Research, vol. 15, no. 1, Jan. 2023, pp. 1-5, doi:10.22159/ijcpr.2023v15i1.2064.



Review Article(s)